Health State Utility Mapping of Rimegepant for the Preventive Treatment of Migraine: Double-Blind Treatment Phase and Open Label Extension (BHV3000-305)
Powell L, L’Italien G, Popoff E, Johnston K, O’Sullivan F, Harris L, Croop R, Coric V, Lipton R. Health State Utility Mapping of Rimegepant for the Preventive Treatment of Migraine: Double-Blind Treatment Phase and Open Label Extension (BHV3000-305). Advances In Therapy 2022, 40: 585-600. PMID: 36417057, PMCID: PMC9898331, DOI: 10.1007/s12325-022-02369-x.Peer-Reviewed Original ResearchConceptsOpen-label extensionEQ-5D utilitiesWeek 12EQ-5DLong-term health-related qualityDouble-blind treatment phaseDouble-blind treatmentPrevention of migraineHealth-related qualityLife Questionnaire version 2.1Migraine-Specific QualityInfluence of treatmentHRQoL improvementResultsBaseline dataIntroductionThe objectiveAdult patientsPoint patientsActive treatmentTrial armsHRQOL measuresPreventive effectPreventive treatmentPlaceboLabel extensionTreatment phaseMonthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000–201)
Johnston K, Harris L, Powell L, Popoff E, Coric V, L’Italien G, Schreiber C. Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000–201). The Journal Of Headache And Pain 2022, 23: 10. PMID: 35038983, PMCID: PMC8903552, DOI: 10.1186/s10194-021-01378-5.Peer-Reviewed Original ResearchConceptsMonthly migraine daysMean monthly migraine daysOpen-label safety studyMigraine daysAcute treatmentSafety studiesLabel Safety StudyMedication-related increasesHealth-related qualityMigraine-Specific QualityEQ-5D utilitiesQuality of lifeDaily PRNMethodsEligible subjectsWeek 52PRN basisMigraine attacksIncremental QALYsLife measuresBackgroundThe objectiveOne-yearMigraineFour subjectsYear historyBaseline